ArticleBritish journal of haematology2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation.
Article in British journal of haematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 70 citations in OpenAlex.
- No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation.Bone marrow transplantation · 2019Trial
- Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Trial
- Expanding the spectrum of post-HSCT hemolysis: from passenger lymphocyte syndrome to host- and graft-associated alloimmune hemolytic anemia.Blood research · 2026Review
- Plasma exchange as an effective treatment for refractory pure red cell aplasia post-ABO-incompatible hematopoietic stem cell transplantation: a rare complication.Oxford medical case reports · 2025Article
- Pure Red Cell Aplasia After ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation Successfully Treated With Daratumumab: Report of Two Cases.Journal of medical cases · 2025Article
- Cord blood therapy for pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: case series and review.Frontiers in oncology · 2025Article
- Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature.World journal of clinical cases · 2024Article
- Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC.Bone marrow transplantation · 2024Article
- Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation.Bone marrow transplantation · 2024Article
- A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia.Annals of hematology · 2024Article
- Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data.Blood advances · 2024Article
- Article
- Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review.Frontiers in oncology · 2024Article
- Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab.Journal of hematology · 2023Article
- Incidence of acquired pure red cell aplasia: a nationwide epidemiologic analysis with 2 registry databases in Japan.Blood advances · 2022Article
- Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.Bone marrow transplantation · 2022Article
- Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.Blood advances · 2022Review
- Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022Article
- Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation.Leukemia research reports · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
Major ABO mismatching is not considered a contraindication to allogeneic haematopoietic stem cell transplantation (HSCT). Modern reduced-intensity conditioning and reduced-toxicity regimens cause much less myeloablation than conventional myeloablative regimens, such as cyclophosphamide with busulfan or total body irradiation, which may affect the incidence of pure red cell aplasia (PRCA). We estimated the incidence and described the natural history of PRCA in patients with major ABO-mismatched donor stem cells. Between 2007 and 2008, 161 (27% of all patients undergoing HSCT) underwent allogeneic HSCT with major ABO-mismatched stem cells and 12 (7·5%) of these patients developed PRCA. Thirty and ninety day T-cell and myeloid cell chimerism and neutrophil and platelet engraftment did not differ between patients who developed PRCA and those who did not. The only risk factor associated with PRCA was the use of a fludarabine/busulfan conditioning regimen. All patients with PRCA needed red cell transfusion for several months after HSCT resulting in significant iron overload. Pure red cell aplasia resolved spontaneously in the majority (seven patients) but only resolved after stopping tacrolimus in three patients. Hence, after major ABO-mismatched HSCT, the incidence of PRCA was 7·5% and it resolved spontaneously or after withdrawal of immunosuppression in the majority of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.